Voriconazole의 용량 변경 현황 분석 및 제안
Analysis of Dose Changing Pattern for Voriconazole and Recommendation
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : Voriconazole is a first-line agent for treatment of invasive aspergillosis. However, the relationship between dose and serum concentration of voriconazole is non-linear, making it very difficult to predict changes in serum level of voriconazole upon dosage change. Here, we reviewed and analyzed cases of changing dose of voriconazole when its serum concentration was not within therapeutic range. Methods : We retrospectively analyzed medical records of adult patients who were hospitalized in Asan Medical Center from January 2010 to December 2015. We excluded cases whose voriconazole level was not in a steady state, those who were administered incompatible drugs, and those who were diagnosed with liver cirrhosis. The number of hospitalization was the unit of analysis. Patients were classified by their initial serum concentration of voriconazole as follows: Group 1 (G1) (TDM1; 1st level 0.5 ㎍/ml), G2 (0.5≤TDM1 1 ㎍/ml), G3 (1≤TDM1 5.5 ㎍/ml (therapeutic range)), G4 (5.5 ≤ TDM1 10 ㎍/ml) and G5 (TDM1≥10 ㎍/ml). Chi-square test and Fisher’s exact test were used to test if there were statistical differences between groups. This study was approved by our Institutional Review Board (No. S2016-1134-0001). Results : A total of 574 cases were analyzed and classified into five groups. We found that 93%, 82%, 87% and 76% of G1, G2, G4 and G5, respectively, reached therapeutic range of voriconazole when their dosages were changed as follows: increased by 2 mg/kg/day, increased by 0.5 mg/kg/day, decreased by ≥1 mg/kg/day and decreased by ≥2 mg/kg/day, respectively. Conclusions : The following dose changing regimen would be more reasonable when serum level of voriconazole is not within therapeutic range: G1, increase by 2-5 mg/kg/day; G2, increase by 0.5-2.5 mg/kg/day; G4, decrease by 1.5-4 mg/kg/day; G5, skip one dose and decrease by 2.5-4 mg/kg/day.
Abstract
Background : Voriconazole is a first-line agent for treatment of invasive aspergillosis. However, the relationship between dose and serum concentration of voriconazole is non-linear, making it very difficult to predict changes in serum level of voriconazole upon dosage change. Here, we reviewed and analyzed cases of changing dose of voriconazole when its serum concentration was not within therapeutic range. Methods : We retrospectively analyzed medical records of adult patients who were hospitalized in Asan Medical Center from January 2010 to December 2015. We excluded cases whose voriconazole level was not in a steady state, those who were administered incompatible drugs, and those who were diagnosed with liver cirrhosis. The number of hospitalization was the unit of analysis. Patients were classified by their initial serum concentration of voriconazole as follows: Group 1 (G1) (TDM1; 1st level 0.5 ㎍/ml), G2 (0.5≤TDM1 1 ㎍/ml), G3 (1≤TDM1 5.5 ㎍/ml (therapeutic range)), G4 (5.5 ≤ TDM1 10 ㎍/ml) and G5 (TDM1≥10 ㎍/ml). Chi-square test and Fisher’s exact test were used to test if there were statistical differences between groups. This study was approved by our Institutional Review Board (No. S2016-1134-0001). Results : A total of 574 cases were analyzed and classified into five groups. We found that 93%, 82%, 87% and 76% of G1, G2, G4 and G5, respectively, reached therapeutic range of voriconazole when their dosages were changed as follows: increased by 2 mg/kg/day, increased by 0.5 mg/kg/day, decreased by ≥1 mg/kg/day and decreased by ≥2 mg/kg/day, respectively. Conclusions : The following dose changing regimen would be more reasonable when serum level of voriconazole is not within therapeutic range: G1, increase by 2-5 mg/kg/day; G2, increase by 0.5-2.5 mg/kg/day; G4, decrease by 1.5-4 mg/kg/day; G5, skip one dose and decrease by 2.5-4 mg/kg/day.
참고문헌 (25)
- Walsh TJ, "Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America", Clin Infect Dis, 46(3), pp.327~360 (2008)
- "KPIC Drug Information"[URL]
- Yamada T, "Saturated metabolism of voriconazole N-Oxidation resulting in nonlinearity of pharmacokinetics of voriconazole at clinical doses", Biol Pharm Bull, 38(10), pp.1496~1503 (2015)
- Dolton MJ, "Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring", Antimicrob Agents Chemother, 56(1-1), pp.4793~4799 (2012)
- Weiler S, "Altered pharmacokinetics of voriconazole in a patient with liver cirrhosis", Antimicrob Agents Chemother, 51(9), pp.3459~3460 (2007)
- Van Wanrooy MJ, "Inflammation is associated with voriconazole trough concentrations", Antimicrob Agents Chemother, 58(12), pp.7098~7101 (2014)
- Han K, "Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients", Clin Pharmacokinet, 50(3), pp.201~214 (2011)
- Han K, "Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients", Antimicrob Agents Chemother, 54(10), pp.4424~4431 (2010)
- Abel S, "Pharmacokinetics, safety and tolerance of voriconazole in renally impaired subjects: two prospective, multicentre, open-label, parallel-group volunteer studies", Clin Drug Investig, 28(7), pp.409~420 (2008)
- Radej J, "Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration", Ther Drug Monit, 33(4), pp.393~397 (2011)
- Lazarus HM, "Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study", J Clin Pharmacol, 42(4), pp.395~402 (2002)
- Denning DW, "Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis", Clin Infect Dis, 34(5), pp.563~571 (2002)
- Moriyama B, "Therapeutic drug monitoring and genotypic screening in the clinical use of voriconazole", Curr Fungal Infect Rep, 9(2), pp.74~87 (2015)
- Park WB, "The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial", Clin Infect Dis, 55(8), pp.1080~1087 (2012)
- Elewa H, "Therapeutic drug monitoring of voriconazole in the management of invasive fungal infections: A critical review", Clin Pharmacokinet, 54(12), pp.1223~1235 (2015)
- Pascual A, "Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics- based analysis of adult patients with invasive fungal infections", Clin Infect Dis, 55(3), pp.381~390 (2012)
- Cojutti P, "Variability of voriconazole trough levels in haematological patients: Influence of comedications with cytochrome P450(CYP) Inhibitors and", or with CYP Inhibitors plus CYP Inducers, 2016, pp.118(6), 474~479
- Vormfelde SV, "Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers", Clin Pharmacol Ther, 86(1), pp.54~61 (2009)
- Baciewicz AM, "Update on rifampin, rifabutin, and rifapentine drug interactions", Curr Med Res Opin, 29(1), pp.1~12 (2013)
- Dolton MJ, "Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing", J Antimicrob Chemother, 69(9), pp.1633~1641 (2014)
- Lee S, "Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers", J Clin Pharmacol, 52(2), pp.195~203 (2012)
- Chen W, "Population pharmacokinetics in China: The dynamics of intravenous voriconazole in critically ill patients with pulmonary disease", Biol Pharm Bull, 38(7), pp.996~1004 (2015)
- Hamada Y, "Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring", J Infect Chemother, 19(3), pp.381~392 (2013)
- "FDA Antiviral Drugs Advisory Committee- Briefing document for voriconazole (oral and intravenous formulations)" (2001)[URL]
- Cota JM, "Antifungal dose adjustment in renal and hepatic dysfunction: Pharmacokinetic and pharmacodynamic considerations", Curr Fungal Infect Rep, 4(2), pp.120~128 (2010)